Peter Thompson Buys 15,000 Shares of CRVS
Insider buying activity at CRVS includes Peter Thompson's recent purchase.
Key Points
- Peter Thompson purchased 15,000 shares of CRVS on June 11, 2026, at a price of $0.00 per share.
- CRVS shares traded near $11.93 with strong interest from institutional investors like BlackRock and State Street.
- Analysts from firms like Goldman Sachs and Oppenheimer maintain a positive outlook on CRVS with 'buy' ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Peter Thompson recently bought 15,000 shares of CRVS on June 11, 2026, at a price of $0.00 per share. This move is part of a broader pattern of insider buying at the company, suggesting confidence in its future prospects.
Insider Buying and Selling at Corvus Pharmaceuticals, Inc.
Several insiders at CRVS have been active in the market. David Scott Moore purchased 21,700 shares at $11.53 each and an additional 15,000 shares at $0.00 on June 11, 2026. On the same day, Richard Van Den Broek, Linda Grais, and Ian Clark each bought 15,000 shares at a price of $0.00. These transactions were not part of pre-planned trading arrangements.
Other Institutional Activity in CRVS
Institutional investors have shown significant interest in CRVS as well. BlackRock, Inc. increased its holdings by 1,104,061 shares to a total of 6,160,422 shares, valued at about $90.1 million. State Street Corp also boosted its stake by 777,769 shares, reaching 3,565,992 shares worth approximately $52.2 million. Meanwhile, Price T Rowe Associates Inc. made a notable addition, acquiring 2,883,195 shares to hold 2,917,300 shares, valued at $42.7 million.
Corvus Pharmaceuticals, Inc. Stock Down 15.7%
Shares of CRVS traded near $11.93. The company has attracted attention from various institutional investors, reflecting confidence in its market potential. The stock has seen significant movements with a range of institutional and insider activities.
Analysts Set New Price Targets
Analysts continue to hold a positive view on CRVS. On April 17, 2026, Goldman Sachs initiated coverage with a 'buy' rating and a $40.00 price target. Oppenheimer reiterated their 'buy' rating with a $33.00 target on March 13, 2026. Jefferies maintained a 'buy' rating, setting a $42.00 target on January 22, 2026. Overall, the consensus remains favorable, with multiple firms maintaining 'buy' ratings.
Bottom Line
Insider and institutional activities at CRVS suggest a strong belief in the company's future potential. While insider purchases like those by Peter Thompson don't guarantee future stock performance, they often indicate management's confidence. Analysts also remain optimistic, with several firms maintaining 'buy' ratings and setting ambitious price targets. As always, investors should consider these factors as part of a broader investment strategy.
Get Corvus Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CRVS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.